Global Contraceptive Market to Surpass USD 33.79 Billion by 2034, Growing at 5.5% CAGR

Contraceptives Market
Contraceptives Market

The global contraceptive market is poised for steady growth, with its valuation expected to rise from USD 19.79 billion in 2024 to USD 33.79 billion by 2034. This expansion represents a compound annual growth rate (CAGR) of 5.5% over the forecast period, driven by increasing awareness of family planning, improved access to contraceptives, and ongoing advancements in reproductive healthcare.

Rising population growth and a global emphasis on reducing unintended pregnancies have significantly boosted the adoption of contraceptive methods. Governments and healthcare organizations worldwide are implementing education campaigns and subsidies to promote contraceptive use, particularly in underserved regions.

Technological advancements, including long-acting reversible contraceptives (LARCs), hormone-free options, and non-invasive delivery methods, are further propelling the market. These innovations cater to diverse consumer preferences and enhance accessibility, contributing to the overall growth trajectory.

As the contraceptive market evolves, key players are investing in research and development to introduce more effective and user-friendly solutions. With increasing consumer demand for convenient and reliable options, the market is set to play a pivotal role in advancing reproductive health and empowering individuals globally.

Key Growth Drivers

  1. Increasing Awareness and Education: Growing public awareness about reproductive health and family planning is driving demand for contraceptive products.
  2. Technological Advancements: Innovations in contraceptive methods, including non-hormonal options and improved delivery systems, are enhancing user experience and effectiveness.
  3. Government Initiatives: Many governments and NGOs are promoting contraceptive use as part of broader health initiatives aimed at reducing unplanned pregnancies and improving maternal health.

Market Players Shaping the Outlook of the Contraceptive Market

The market is a competitive and rapidly evolving industry. Key players focus on diverse techniques to stay ahead of the competition and augment their presence in the market. Effective strategies are to acquire or collaborate with companies to improve their product portfolio and market penetration.

Companies, in addition to acquisitions and collaborations, prioritize gaining FDA approvals to ensure the safety and effectiveness of their products, giving them a competitive edge over competitors who may not have received the necessary approvals.

The leading companies are well known for their innovative products and commitment to providing safe and effective contraception to women globally. By leveraging these key strategies, they are able to stay ahead of the competition and continue to grow their businesses in a rapidly evolving market.

Recent Developments in the Contraceptive Market

  • In December 2023, United Kingdom’s researchers started trials for a non-hormonal male birth control pill, YCT-529, developed by Quotient Sciences. The trial involves 16 British men, aiming to shift the burden of preventing unwanted pregnancies from women to men. YCT-529 blocks access to vitamin A, preventing infertility.
  • In December 2023, Aditxt acquired Evofem Biosciences, creator of the first hormone-free contraceptive gel, Phexxi, under a definitive agreement focusing on health innovations and women’s health.
  • In October 2023, the Indian Council of Medical Research (ICMR) completed clinical trials for the world’s first injectable male contraceptive, demonstrating its safety and efficacy without serious side effects.
  • In July 2023, The FDA approved Perrigo’s Opill, the first nonprescription birth control pill in the United States, making it more effective than other nonprescription methods, potentially expanding access to contraception.
  • In June 2023, the Biden-Harris Administration announced a public-private partnership with Upstream to improve access to contraception and address growing health disparities in the United States.
  • In March 2023, NEXT Life Sciences plans to launch Plan A™, a safe, effective, and reversible male contraceptive product. The company will participate in LSI’s 2023 Emerging Medtech Summit in Dana Point, California, to showcase its product and engage with investors.

Key Companies

  • Bayer AG Pfizer Inc.
  • Janssen Global Services, LLC
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Allergan Plc.
  • Reckitt Benckiser Group plc.
  • Veru Inc.
  • Church & Dwight Co., Inc.
  • Medisafe Distribution Inc.
  • Cooper Surgical, Inc.
  • Mayer Laboratories, Inc.
  • Pfizer Inc.
  • The Female Health Company
  • Exeltis USA, Inc.

A Comprehensive Full Report

Key Segments

By Product:

  • Drugs
    • Oral Contraceptive Pills
    • Injectable Contraceptive
    • Topical Contraceptive
  • Devices
    • Condoms
    • Diaphragms
    • Contraceptive Sponges
    • Vaginal Rings
    • Cervical Cap
    • Subdermal Implants
    • Intra-uterine Devices
      • Copper
      • Hormonal

By Gender:

  • Female
  • Male

By End User:

  • Institutional Sales
    • Hospitals
    • Specialty Clinics
  • Retail Sales
    • Retail Pharmacy
    • Drug Stores
    • Supermarkets or Hypermarkets
  • Online Sales

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these